CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 360 enrolled
Drug / intervention
FPNS +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00519636
NCT00519636Phase 4Completed

A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis

GlaxoSmithKline·interventional·Posted Aug 22, 2007·Updated Dec 9, 2016

In Brief

A Phase 4 clinical trial evaluating FPNS, FFNS, and 2 other interventions for Rhinitis, Allergic, Perennial. Completed, enrolled 360 participants across 28 sites.

Detailed Summary

The purpose of this replicate study to FFU105924 is to provide data on subject preference of FFNS as compared with FPNS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2007
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.9 years ago

Interventions

FPNSdrug

fluticasone propionate nasal spray

FFNSdrug

fluticasone furoate nasal spray

placebo FFNSdrug

placebo nasal spray matching fluticasone furoate nasal spray

placebo FPNSdrug

placebo nasal spray matching fluticasone propionate nasal spray